P. A. Boone

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities

E. Estey, M. Konopleva, Z. Estrov, 2010 .

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2011 .

Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.

G. Garcia-Manero, J. Cortes, T. Kadia, 2011, Journal of Clinical Oncology.

Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia

H. Kantarjian, F. Ravandi, G. Borthakur, 2008 .

A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007 .

Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .